Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
119 hedge funds and large institutions have $1.04B invested in Eagle Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 34 reducing their positions, and 26 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
1% less funds holding
Funds holding: 120 → 119 (-1)
4% less capital invested
Capital invested by funds: $1.08B → $1.04B (-$39.9M)
31% less call options, than puts
Call options by funds: $7.06M | Put options by funds: $10.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.5M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$19.9M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$14.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$10.5M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$6.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$12.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$9.15M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$3.85M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.84M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$3.83M |
EGRX Hedge Fund Activity: Q3 2015 in Review
119 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2015, worth a combined $1.04B — down 3.7% from $1.08B a quarter earlier.
Fund positioning in EGRX was balanced in Q3 2015: 26 funds opened new positions, 26 closed out, 50 added to existing stakes and 34 trimmed.
The largest buyer was Vanguard Group, adding an estimated $21.5M. The largest seller was Bogle Investment Management, exiting entirely with an estimated $12.9M sold.
- 119 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2015, down from 120 in Q2 2015.
- Funds reported $1.04B of Eagle Pharmaceuticals, Inc. stock for Q3 2015, down 3.7% quarter-over-quarter.
- 26 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2015 and 26 closed out, a net change of 0 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2015 was Vanguard Group, an estimated $21.5M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2015 was Bogle Investment Management, an estimated $12.9M sold.
Based on aggregated 13F filings for Q3 2015.